Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$38.93

0.83 (2.18%)

10:29
11/25/16
11/25
10:29
11/25/16
10:29

GlaxoSmithKline announces EU regulatory submission for shingles vaccine

GlaxoSmithKline announced the regulatory submission of a Marketing Authorisation Application to the European Medicines Agency seeking approval for its candidate shingles vaccine, Shingrix, for the prevention of herpes zoster in people aged 50 years or over. The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles and its complications. The phase III clinical trial programme showed that by reducing the incidence of shingles, the candidate vaccine also reduced the overall incidence of postherpetic neuralgia, a form of chronic pain associated with shingles. Regulatory approval is being sought for the vaccine to be given intramuscularly in two doses, with a two-to-six month interval between doses. The regulatory submission for the candidate vaccine is based on a comprehensive phase III clinical trial programme evaluating its efficacy, safety and immunogenicity in more than 37,000 people. This includes the ZOE-50 and ZOE-70 studies published in the New England Journal of Medicine in April 2015 and September 2016, respectively. The submission to the EMA follows regulatory submissions to the U.S. FDA in October of this year and to Canada regulatory authorities earlier this month, with a Japan submission planned for 2017.

  • 29

    Nov

GSK GlaxoSmithKline
$38.93

0.83 (2.18%)

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.

TODAY'S FREE FLY STORIES

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

20:43
01/16/18
01/16
20:43
01/16/18
20:43
Downgrade
NuVasive rating change at Wells Fargo »

NuVasive downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

20:38
01/16/18
01/16
20:38
01/16/18
20:38
Recommendations
Juno Therapeutics, Celgene, Acquired by GILD 9/17, Gilead analyst commentary at Citi »

Juno could be worth $110…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KITE

Acquired by GILD 9/17

GILD

Gilead

$80.25

1.23 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

SNP

Sinopec

$83.07

-1 (-1.19%)

20:35
01/16/18
01/16
20:35
01/16/18
20:35
Upgrade
Sinopec rating change at Jefferies »

Sinopec upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

20:34
01/16/18
01/16
20:34
01/16/18
20:34
Downgrade
Shell Midstream rating change at Stifel »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

AVXS

AveXis

$105.01

-12.49 (-10.63%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Syndicate
AveXis 3.921M share Secondary priced at $102.00 »

Goldman Sachs, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OZRK

Bank of the Ozarks

$52.23

-0.24 (-0.46%)

20:26
01/16/18
01/16
20:26
01/16/18
20:26
Downgrade
Bank of the Ozarks rating change at Keefe Bruyette »

Bank of the Ozarks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 30

    Jan

WP

Worldpay

$78.26

0.66 (0.85%)

, VNTV

Symbol changed to WP

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Initiation
Worldpay, Symbol changed to WP initiated at Goldman Sachs »

Worldpay reinstated with…

WP

Worldpay

$78.26

0.66 (0.85%)

VNTV

Symbol changed to WP

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.24

0.05 (0.16%)

, GS

Goldman Sachs

$258.46

1.43 (0.56%)

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$31.24

0.05 (0.16%)

GS

Goldman Sachs

$258.46

1.43 (0.56%)

USB

U.S. Bancorp

$57.17

0.19 (0.33%)

FAST

Fastenal

$55.44

-0.15 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

  • 15

    Feb

C

Citi

$77.11

0.27 (0.35%)

20:20
01/16/18
01/16
20:20
01/16/18
20:20
Downgrade
Citi rating change at Keefe Bruyette »

Citi downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 18

    Jan

  • 24

    Jan

O

Realty Income

$52.94

0.22 (0.42%)

19:12
01/16/18
01/16
19:12
01/16/18
19:12
Hot Stocks
Realty Income raises monthly dividend to 21.9c per share from 21.25c »

Realty Income announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:05
01/16/18
01/16
19:05
01/16/18
19:05
Hot Stocks
New Gold sees FY18 gold production 525,000-595,000 ounces »

Sees FY18 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports Q4 gold production 154,446 ounces »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports FY17 gold production 430,864 ounces »

Reports FY17 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$80.42

-0.12 (-0.15%)

18:50
01/16/18
01/16
18:50
01/16/18
18:50
Earnings
PayPal sees FY18 revenue $15B-$15.25B, consensus $15.35B »

Backs FY18 TPV Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

CE

Celanese

$109.67

-1.67 (-1.50%)

18:32
01/16/18
01/16
18:32
01/16/18
18:32
Hot Stocks
Celanese increases the price of low density polyethylene to 4c »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

RIG

Transocean

$11.47

-0.73 (-5.98%)

18:27
01/16/18
01/16
18:27
01/16/18
18:27
Hot Stocks
Transocean shareholders show 'overwhelming support' for Songa transaction »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

WMT

Walmart

$100.69

-0.18 (-0.18%)

18:13
01/16/18
01/16
18:13
01/16/18
18:13
Periodicals
Wal-Mart COO to be named international CEO, Reuters says »

Wal-Mart Stores COO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CME

CME Group

$152.20

-0.53 (-0.35%)

18:05
01/16/18
01/16
18:05
01/16/18
18:05
Hot Stocks
CME reaches daily trading volume record for Henry Hub Nat Gas futures on Jan 12 »

CME Group announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 01

    Feb

CE

Celanese

$109.67

-1.67 (-1.50%)

18:02
01/16/18
01/16
18:02
01/16/18
18:02
Hot Stocks
Celanese announces price increases for engineered materials polymer products »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SRC

Spirit Realty

$8.07

-0.03 (-0.37%)

17:46
01/16/18
01/16
17:46
01/16/18
17:46
Hot Stocks
Spirit Realty funds $35M into Shopko master lease »

Spirit Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

17:45
01/16/18
01/16
17:45
01/16/18
17:45
Conference/Events
Nutanix management to meet with Piper Jaffray »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

17:41
01/16/18
01/16
17:41
01/16/18
17:41
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Juno Therapeutics…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

NEWA

Newater Technology

$15.80

2.8 (21.54%)

VRS

Verso

$17.00

0.06 (0.35%)

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

RNST

Renasant

$43.86

0.15 (0.34%)

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

CSX

CSX

$58.13

-1.12 (-1.89%)

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

XON

Intrexon

$13.77

-0.94 (-6.39%)

BOOT

Boot Barn

$19.10

-0.15 (-0.78%)

F

Ford

$13.10

-0.13 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 01

    Mar

  • 25

    Mar

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

NRZ

New Residential

$17.63

-0.11 (-0.62%)

17:35
01/16/18
01/16
17:35
01/16/18
17:35
Earnings
Breaking Earnings news story on New Residential »

New Residential sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

17:30
01/16/18
01/16
17:30
01/16/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Exelixis »

Exelixis up 3.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.